HC Wainwright & Co. Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $27

Benzinga · 05/09 19:25
HC Wainwright & Co. analyst Oren Livnat maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price target from $25 to $27.